Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.36 |
| ▸ | MERTK | Q12866 | 2/20 | 0.36 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.36 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615707 | 0.73 | CHRM2 (0.49) | OPRK1 | |
| SCHEMBL13822147 | 0.73 | RPS6KA5 (0.43) | CYP11B1CYP11B2RPS6KA5AKT1AKT2 | |
| SCHEMBL23296207 | 0.73 | IDH1 (0.40) | IDH1 | |
| SCHEMBL23296212 | 0.72 | CNR2 (0.40) | IDH1 | |
| SCHEMBL20070737 | 0.70 | TRPV6 (0.50) | CYP11B1 | |
| SCHEMBL22031240 | 0.68 | RET (0.43) | TLR7 | |
| SCHEMBL11773404 | 0.67 | CHRM2 (0.53) | OPRK1CYP2D6 | |
| SCHEMBL12835958 | 0.67 | OPRM1 (0.46) | OPRK1 | |
| SCHEMBL22812025 | 0.66 | ALDH1A1 (0.48) | — | |
| SCHEMBL18713232 | 0.66 | CHRNB2 (0.47) | CYP11B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | CYP11B1 727/4885CYP11B2 1048/4885TLR7 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.